The Economic Burden of Multiple Sclerosis in the United States

US Health Care Spending by Payer and Health Condition, 1996-2016

(2020) Joseph L. Dieleman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Current and projected future economic burden of Parkinson’s disease in the U.S.

(2020) Wenya Yang et al.   npj Parkinsons Disease

The retirement rate due to multiple sclerosis has decreased since 1995– A retrospective study in a Finnish central hospital

(2020) T. Heinonen et al.   Multiple Sclerosis and Related Disorders

The prevalence of MS in the United States

(2019) Mitchell T. Wallin et al.   NEUROLOGY

Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes

(2019) Wylezinski et al.   Journal of Clinical Medicine

Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA

(2017) Daniel M. Hartung   Neurotherapeutics

All-Cause Health Care Utilization and Costs Associated with Newly Diagnosed Multiple Sclerosis in the United States

(2016) Carl V. Asche et al.   JOURNAL OF MANAGED CARE PHARMACY

Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis

(2015) Sander Yermakov et al.   JOURNAL OF MEDICAL ECONOMICS

Cost of illness for neuromuscular diseases in the United States

(2013) Jane Larkindale et al.   MUSCLE & NERVE

Environmental Risk Factors for Multiple Sclerosis: A Review with a Focus on Molecular Mechanisms

(2012) Cullen O’Gorman et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs

(2009) Howard G. Birnbaum et al.   CURRENT MEDICAL RESEARCH AND OPINION

Assessment of Caregiver Burden in Families of Persons with Multiple Sclerosis

(2009) Marijean Buhse   JOURNAL OF NEUROSCIENCE NURSING